{ "items": [ "\n\n
\n \n Journal article\n \n
\n \n\n \n \n \nBrunen D. et al, (2013), Cell Cycle, 12, 2960 - 2968
\n \n \n \n\n \n
\n \n \n\n \n Conference paper\n \n
\n \n\n \n \n \nChurch D. et al, (2013), EUROPEAN JOURNAL OF CANCER, 49, S484 - S484
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nChurch DN. et al, (2013), Chin Clin Oncol, 2
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nMidgley RS. and Kerr DJ., (2013), J Clin Oncol, 31
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nSchwartz GK. et al, (2013), Invest New Drugs, 31, 370 - 380
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nDutton SJ. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nDomingo E. et al, (2013), J Pathol, 229, 441 - 448
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nHuijbers A. et al, (2013), Ann Oncol, 24, 179 - 185
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nLefevre JH. et al, (2012), J Hum Genet, 57, 709 - 716
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nBeggs AD. et al, (2012), Oncotarget, 3, 1348 - 1355
\n \n \n \n\n \n
\n \n \n\n \n Conference paper\n \n
\n \n\n \n \n \nMidgley RS. et al, (2012), ANNALS OF ONCOLOGY, 23, 181 - 182
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nDunlop MG. et al, (2012), Nature Genetics, 44, 770 - 776
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nDunlop MG. et al, (2012), Nat Genet, 44, 770 - 776
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nMidgley RS. et al, (2012), 444 - 454
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nJones AM. et al, (2012), Gut, 61, 248 - 254
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nJones AM. et al, (2012), Gut, 61, 248 - 254
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nChurch D. et al, (2012), Dig Dis, 30 Suppl 2, 27 - 33
\n \n \n \n\n \n
\n \n \n\n \n Chapter\n \n
\n \n\n \n \n \nChurch DN. et al, (2012), Biotargets of Cancer in Current Clinical Practice, 245 - 272
\n \n \n \n\n \n
\n \n \n\n \n Journal article\n \n
\n \n\n \n \n \nSchwartz GK. et al, (2012), Investigational New Drugs, 1 - 11
\n \n \n \n\n \n
\n \n \n\n \n Chapter\n \n
\n \n\n \n \n \nYanagisawa Y. et al, (2011), Advances in the Pharmacological Management of Metastatic Colorectal Cancer, 18 - 29
\n \n \n \n\n \n
\n \n \n